首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Journal Of Clinical Oncology

Journal Of Clinical Oncology杂志,由American Society of Clinical Oncology出版,于1983年创刊,Biweekly,出版语言English,ISSN:0732-183X,E-ISSN:1527-7755。

投稿咨询
Journal Of Clinical Oncology
Journal Of Clinical Oncology
Journal Of Clinical Oncology
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
1区
影响因子
44.7
CiteScore
14.2
期刊收录
SCI、SCIE

Journal Of Clinical Oncology(中文译名:《临床肿瘤学杂志》),ISSN:0732-183X,EISSN:1527-7755,是American Society of Clinical Oncology出版的国际性学术期刊,创刊于1983年,以Biweekly形式稳定发行,2026年总发文量约308篇。该刊采用非OA开放访问,学科归属为医学 - 肿瘤学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达44.7,2025年期刊CiteScore为14.2,2025年期刊自引率约1.6%,在中科院期刊分区体系中位列医学大类1区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Journal Of Clinical Oncology长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期约2月,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USACanada、CHINA MAINLAND、England、France、Japan、GERMANY (FED REP GER)等为核心发文国家与地区;HARVARD UNIVERSITYUNIVERSITY OF TEXAS SYSTEM、UNIVERSITY OF CALIFORNIA SYSTEM、MEMORIAL SLOAN KETTERING CANCER CENTER、DANA-FARBER CANCER INSTITUTE、UNICANCER、MAYO CLINIC等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
1区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
1区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
1区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 7 / 333

98

学科:ONCOLOGY SCIE Q1 7 / 333

98.05

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 6 / 328

98.3

学科:ONCOLOGY SCIE Q1 7 / 328

98.02


中国学者近期发文

1
Radiosurgery for Small Cell Lung Cancer Brain Metastases: Comparing the JLGK0901 and BWH/DFCI Trial

Author:Rusthoven, Chad G.; Serizawa, Toru; Yamamoto, Masaaki

Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 12, pp. 1174-1175. DOI: 10.1200/JCO-25-01794

2
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Stud

Author:Licitra, Lisa; Tahara, Makoto; Harrington, Kevin; Olivera Hurtado de Mendoza, Mivael; Guo, Ye; Aksoy, Sercan; Fang, Meiyu; Csőszi, Tibor; Klochikhin, Mikhail; Bueno de Oliveira, Thiago; Takahashi, Shunji; Yang, Muh-Hwa; Swiecicki, Paul L.; Even, Caroline; Fayette, Jérome; Dutcus, Corina; Okpara, Chinyere E.; Shen, Juan; Benjamin, Kimberly; Gumuscu, Burak; Haddad, Robert I

Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 12, pp. 1098-1107. DOI: 10.1200/JCO-25-00570

3
Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Tria

Author:Zhu, Hai-Dong; Fan, Wei-Jun; Zhao, Chang; Wang, Song; Li, Yu-Liang; Jin, Zhi-Cheng; Zhang, Zhe-Wei; Guo, Jin-He; Cheng, Hong-Tao; Zhang, Qi; Lu, Jian; Zeng, Yong-Yi; Lv, Wei-Fu; Xu, Hao; Shao, Hai-Bo; Xu, Wei-Guo; Zhao, Xu-Ya; Gu, Shan-Zhi; Lin, Hai-Lan; Zheng, Wen-Heng; Piao, Long-Zhen; Song, Yu-Sheng; Zhao, Jian-Bo; Wang, Yuan-Cheng; Hou, Zhi-Guo; Sun, Ying; Guan, Ni; Huang, Ming; Yang, Wei-Zhu; Ji, Jian-Song; Teng, Gao-Jun

Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 11, pp. 959-969. DOI: 10.1200/JCO-25-01796

4
Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001

Author:Yan, Wenqiang; Du, Chenxing; Lv, Rui; Zou, Hesong; Zhang, Shuaishuai; Yu, Tengteng; Yan, Yuting; Zhang, Yanlei; Peng, Shuixiu; Wang, Tingyu; Deng, Shuhui; Huang, Wenyang; Yi, Shuhua; Zou, Dehui; Cheng, Tao; Wang, Jianxiang; Chang, Alex H.; Qiu, Lugui; An, Gang

Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 11, pp. 992-1002. DOI: 10.1200/JCO-25-01969

5
Reply to: Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyon

Author:Wermke, Martin; Gambardella, Valentina; Kuboki, Yasutoshi; Felip, Enriqueta; Sanmamed, Miguel F.; Alese, Olatunji B.; Sayehli, Cyrus M.; Arriola, Edurne; Wolf, Jürgen; Villaruz, Liza C.; Bertulis, Julia; Studeny, Matus; Bouzaggou, Mohamed; Fang, Xiaoyan; Morgensztern, Daniel

Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 11, pp. 1062-1064. DOI: 10.1200/JCO-25-02654

6
Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Tria

Author:Mei, Wei-Jian; Wang, Xiao-Zhong; Zhang, Xuan; Sun, Yue-Ming; Yang, Chun-Kang; Lin, Jun-Zhong; Wu, Zu-Guang; Zhang, Rui; Wang, Wei; Li, Yong; Zhuang, Ye-Zhong; Lei, Jian; Wan, Xiang-Bin; Ren, Ying-Kun; Cheng, Yong; Li, Wen-Liang; Wang, Zi-Qiang; Xu, Dong-Bo; Mo, Xian-Wei; Ju, Hai-Xing; Ye, Sheng-Wei; Zhao, Jing-Lin; Zhang, Hong; Gao, Yuan-Hong; Zeng, Zhi-Fan; Xiao, Wei-Wei; Zhang, Xiao-Peng; Li, Yun-Feng; Xie, E; Feng, Yi-Fei; Tang, Jing-Hua; Wu, Xiao-Jun; Chen, Gong; Li, Li-Ren; Lu, Zhen-Hai; Wan, De-Sen; Bei, Jin-Xin; Pan, Zhi-Zhong; Yu, Jie-Hai; Ding, Pei-Rong

Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 11, pp. 970-980. DOI: 10.1200/JCO-25-00731

7
Mifamurtide in Nonmetastatic High-Grade Osteosarcom

Author:Li, Huan-Ning

Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 11, pp. 1060-1060. DOI: 10.1200/JCO-25-02154

8
Development of a Classifier for Metabolic Subtypes of Nasopharyngeal Carcinoma to Guide Personalized Immunotherapy Strategies: Biomarker Analysis of the Phase III CONTINUUM and DIPPER Trial

Author:Huang, Sai-Wei; Liang, Ye-Lin; Tao, Ya-Lan; Li, Wen-Fei; Zhou, Guan-Qun; Mao, Yan-Ping; Guo, Rui; Chen, Lei; Xu, Sha; Liu, Xu; Zhang, Ning; Liu, Fang; Shen, Liang-Fang; Zhou, Yang-Ying; Yuan, Ya-Wei; Zou, Guo-Rong; Jin, Feng; Tang, Ling-Long; Sun, Ying; Li, Ying-Qin; Ma, Jun; Liu, Na

Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 11, pp. 1028-1039. DOI: 10.1200/JCO-25-02111

9
Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyon

Author:Chen, Yitian; Liu, Li; Ming, Yang; Chen, Ligang

Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 11, pp. 1061-1062. DOI: 10.1200/JCO-25-01894

10
Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Stud

Author:Zhou, Huaqiang; Zhao, Hongyun; Hou, Xue; Wang, Yongsheng; He, Zhiyong; Li, Yongsheng; Ma, Yuxiang; Zhao, Yuanyuan; Huang, Yan; Chen, Likun; Xiao, Sa; Zhu, Hai; Zhu, Yi; Fang, Wenfeng; Zhang, Li; Yang, Yunpeng

Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 10, pp. 893-902. DOI: 10.1200/JCO-25-01929


在线咨询

Journal Of Clinical Oncology

国际简称:J CLIN ONCOL参考译名:临床肿瘤学杂志

年发文量:308 CiteScore:14.2 是否预警:否 Gold OA文章占比:36.39% 研究类文章占比:97.08%

杂志社联系方式:AMER SOC CLINICAL ONCOLOGY, 2318 MILL ROAD, STE 800, ALEXANDRIA, USA, VA, 22314

Journal Of Clinical Oncology